Parkinson's Disease Iron Deposition Caused by Nitric Oxide-Induced Loss of β-Amyloid Precursor Protein

Elevation of both neuronal iron and nitric oxide (NO) in the substantia nigra are associated with Parkinson's disease (PD) pathogenesis. We reported previously that the Alzheimer-associated β-amyloid precursor protein (APP) facilitates neuronal iron export. Here we report markedly decreased APP expression in dopaminergic neurons of human PD nigra and that APP−/− mice develop iron-dependent nigral cell loss. Conversely, APP-overexpressing mice are protected in the MPTP PD model. NO suppresses APP translation in mouse MPTP models, explaining how elevated NO causes iron-dependent neurodegeneration in PD.

[1]  DuhamelAlain,et al.  Targeting chelatable iron as a therapeutic modality in Parkinson's disease. , 2014 .

[2]  D. Kosman,et al.  sAPP modulates iron efflux from brain microvascular endothelial cells by stabilizing the ferrous iron exporter ferroportin , 2014, EMBO reports.

[3]  Blaine R. Roberts,et al.  An iron–dopamine index predicts risk of parkinsonian neurodegeneration in the substantia nigra pars compacta , 2014 .

[4]  H. Bergman,et al.  Redundant dopaminergic activity may enable compensatory axonal sprouting in Parkinson disease , 2014, Neurology.

[5]  John R. Yates,et al.  Isogenic Human iPSC Parkinson’s Model Shows Nitrosative Stress-Induced Dysfunction in MEF2-PGC1α Transcription , 2013, Cell.

[6]  Michael D. Pluth,et al.  Identification and Rescue of α-Synuclein Toxicity in Parkinson Patient–Derived Neurons , 2013, Science.

[7]  A. Bush,et al.  Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease , 2013, Annals of neurology.

[8]  A. Bush,et al.  Amine oxidase activity of β-amyloid precursor protein modulates systemic and local catecholamine levels , 2013, Molecular Psychiatry.

[9]  Blaine R. Roberts,et al.  The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson’s disease , 2012, The Journal of experimental medicine.

[10]  Blaine R. Roberts,et al.  Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export , 2012, Nature Medicine.

[11]  A. V. Santhanam,et al.  Endothelial Nitric Oxide Modulates Expression and Processing of Amyloid Precursor Protein , 2010, Circulation research.

[12]  C. Masters,et al.  Iron-Export Ferroxidase Activity of β-Amyloid Precursor Protein Is Inhibited by Zinc in Alzheimer's Disease , 2010, Cell.

[13]  F. Jourdan,et al.  Early locus coeruleus degeneration and olfactory dysfunctions in Tg2576 mice , 2009, Neurobiology of Aging.

[14]  Charles Duyckaerts,et al.  Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease , 2008, Proceedings of the National Academy of Sciences.

[15]  M. Elstner,et al.  Individual dopaminergic neurons show raised iron levels in Parkinson disease , 2007, Neurology.

[16]  Xudong Huang,et al.  An Iron-responsive Element Type II in the 5′-Untranslated Region of the Alzheimer's Amyloid Precursor Protein Transcript* , 2002, The Journal of Biological Chemistry.

[17]  D. D. Di Monte,et al.  Inhibition of Monoamine Oxidase Contributes to the Protective Effect of 7‐Nitroindazole Against MPTP Neurotoxicity , 1997, Journal of neurochemistry.

[18]  T. Dawson,et al.  Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[19]  G. Dawson,et al.  β-amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity , 1995, Cell.

[20]  S. Snyder,et al.  The iron-responsive element binding protein: a target for synaptic actions of nitric oxide. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[21]  J. Edwardson,et al.  Transferrin receptors in the Parkinsonian midbrain , 1994, Neuropathology and applied neurobiology.

[22]  G Werner-Felmayer,et al.  Translational regulation via iron‐responsive elements by the nitric oxide/NO‐synthase pathway. , 1993, The EMBO journal.

[23]  L. Defebvre,et al.  Targeting Chelatable Iron as a Therapeutic Modality in Parkinson ’ s Disease , 2016 .